Brokerages Set Regulus Therapeutics Inc. (NASDAQ:RGLS) Target Price at $10.80

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $10.80.

A number of equities research analysts have recently issued reports on the company. HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research report on Monday, November 11th. StockNews.com upgraded Regulus Therapeutics to a "sell" rating in a research report on Tuesday, September 17th. Finally, Oppenheimer reiterated an "outperform" rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a research report on Wednesday, August 14th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of RGLS. Creative Planning purchased a new position in shares of Regulus Therapeutics during the third quarter worth $26,000. SG Americas Securities LLC purchased a new position in shares of Regulus Therapeutics during the third quarter worth $33,000. Jane Street Group LLC purchased a new position in shares of Regulus Therapeutics during the third quarter worth $46,000. Barclays PLC boosted its position in shares of Regulus Therapeutics by 285.2% during the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company's stock worth $132,000 after buying an additional 62,549 shares during the period. Finally, Rhumbline Advisers purchased a new position in shares of Regulus Therapeutics during the second quarter worth $136,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Regulus Therapeutics Stock Performance

Shares of RGLS stock traded up $0.07 during trading hours on Friday, reaching $1.47. The company had a trading volume of 288,016 shares, compared to its average volume of 500,064. The stock has a fifty day moving average of $1.53 and a 200-day moving average of $1.76. The company has a market capitalization of $96.29 million, a price-to-earnings ratio of -1.37 and a beta of 1.63. Regulus Therapeutics has a 12-month low of $1.08 and a 12-month high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.03). On average, analysts forecast that Regulus Therapeutics will post -0.88 EPS for the current year.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.